Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling

Wei Hu, Stefan Nessler, Bernhard Hemmer, Todd N. Eagar, Lawrence P. Kane, S. Rutger Leliveld, Andreas Müller-Schiffmann, Anne R. Gocke, Amy Lovett-Racke, Li Hong Ben, Rehana Z. Hussain, Andreas Breil, Jeffrey L. Elliott, Krishna Puttaparthi, Petra D. Cravens, Mahendra P. Singh, Benjamin Petsch, Lothar Stitz, Michael K. Racke, Carsten KorthOlaf Stüve

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

The primary biological function of the endogenous cellular prion protein has remained unclear. We investigated its biological function in the generation of cellular immune responses using cellular prion protein gene-specific small interfering ribonucleic acid in vivo and in vitro. Our results were confirmed by blocking cellular prion protein with monovalent antibodies and by using cellular prion protein-deficient and-transgenic mice. In vivo prion protein gene-small interfering ribonucleic acid treatment effects were of limited duration, restricted to secondary lymphoid organs and resulted in a 70 reduction of cellular prion protein expression in leukocytes. Disruption of cellular prion protein signalling augmented antigen-specific activation and proliferation, and enhanced T cell receptor signalling, resulting in zeta-chain-associated protein-70 phosphorylation and nuclear factor of activated T cells/activator protein 1 transcriptional activity. In vivo prion protein gene-small interfering ribonucleic acid treatment promoted T cell differentiation towards pro-inflammatory phenotypes and increased survival of antigen-specific T cells. Cellular prion protein silencing with small interfering ribonucleic acid also resulted in the worsening of actively induced and adoptively transferred experimental autoimmune encephalomyelitis. Finally, treatment of myelin basic protein1-11 T cell receptor transgenic mice with prion protein gene-small interfering ribonucleic acid resulted in spontaneous experimental autoimmune encephalomyelitis. Thus, central nervous system autoimmune disease was modulated at all stages of disease: the generation of the T cell effector response, the elicitation of T effector function and the perpetuation of cellular immune responses. Our findings indicate that cellular prion protein regulates T cell receptor-mediated T cell activation, differentiation and survival. Defects in autoimmunity are restricted to the immune system and not the central nervous system. Our data identify cellular prion protein as a regulator of cellular immunological homoeostasis and suggest cellular prion protein as a novel potential target for therapeutic immunomodulation.

Original languageEnglish (US)
Pages (from-to)375-388
Number of pages14
JournalBrain
Volume133
Issue number2
DOIs
StatePublished - Feb 2010

Keywords

  • Immunosuppression
  • Prion
  • Small interfering RNA
  • T cell signaling

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling'. Together they form a unique fingerprint.

  • Cite this

    Hu, W., Nessler, S., Hemmer, B., Eagar, T. N., Kane, L. P., Leliveld, S. R., Müller-Schiffmann, A., Gocke, A. R., Lovett-Racke, A., Ben, L. H., Hussain, R. Z., Breil, A., Elliott, J. L., Puttaparthi, K., Cravens, P. D., Singh, M. P., Petsch, B., Stitz, L., Racke, M. K., ... Stüve, O. (2010). Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain, 133(2), 375-388. https://doi.org/10.1093/brain/awp298